[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-334718-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-334718-en":130},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","st6gal1-is-associated-with-poor-response-to-chemoradiation-in-rectal-cancer-original-research-abstract","ST6GAL1 is associated with poor response to chemoradiation in rectal cancer - Original Research - Abstract","","ST6GAL1 is examined as a potential mediator of resistance to chemoradiation in locally advanced rectal cancer. Colorectal cancer incidence and the variability of treatment response motivate the search for predictors of outcomes after chemoradiation followed by surgery. Five patient-derived organoid models were used, including a ST6GAL1 knockdown line, and chemoradiation effects were evaluated using immunostaining for ST6GAL1 and Cleaved Caspase-3. In a tissue microarray of 26 patients with paired pre- and post-treatment specimens, increased ST6GAL1 staining after therapy correlated with a worse pathological grade of response, supporting ST6GAL1-linked treatment resistance in vivo.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/st6gal1-is-associated-with-poor-response-to-chemoradiation-in-rectal-cancer-original-research-abstract/334718/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/st6gal1-is-associated-with-poor-response-to-chemoradiation-in-rectal-cancer-original-research-abstract/334718.png","ImageObject",300,407,{"name":42,"@type":43},"Ava Thompson","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-11-04","2026-09-21",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",7,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"What role does ST6GAL1 have in rectal cancer response to chemoradiation?","Question",{"text":63,"@type":64},"ST6GAL1 is associated with resistance to chemoradiation. Higher ST6GAL1 levels after treatment correlate with a worse pathological grade of response in patient samples.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"How were organoid models used to test ST6GAL1 during chemoradiation?",{"text":68,"@type":64},"Five organoid models derived from primary rectal cancers were treated with chemoradiation, and ST6GAL1 and Cleaved Caspase-3 were assessed after treatment. One model included ST6GAL1 knockdown via lentiviral transduction to evaluate changes in apoptosis.",{"name":70,"@type":61,"acceptedAnswer":71},"What did the tissue microarray show about ST6GAL1 staining and outcomes?",{"text":72,"@type":64},"In the tissue microarray, 42% of samples showed increased ST6GAL1-positive tumor cell staining after chemoradiation. Post-treatment increased staining and worse response grades were significantly correlated.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},334718,1790399867,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,106,110,114,119,122,126],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},6,"Technology",50,"technology",{"id":55,"doc_module":4,"doc_module_name":25,"category_name":107,"show_sort_weight":108,"slug":109},"Healthcare",40,"healthcare",{"id":111,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":112,"slug":113},8,30,"research-report",{"id":115,"doc_module":4,"doc_module_name":25,"category_name":116,"show_sort_weight":117,"slug":118},9,"Religion & Spirituality",20,"religion-spirituality",{"id":117,"doc_module":4,"doc_module_name":25,"category_name":120,"show_sort_weight":117,"slug":121},"World Cup","world-cup",{"id":123,"doc_module":4,"doc_module_name":25,"category_name":124,"show_sort_weight":123,"slug":125},10,"Lifestyle","lifestyle",{"id":127,"doc_module":4,"doc_module_name":25,"category_name":128,"show_sort_weight":97,"slug":129},19,"General","general",{"code":4,"msg":82,"data":131},{"doc_id":79,"user_id":132,"nickname":42,"user_avatar":133,"doc_module":4,"category_id":111,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":55,"language":139,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":140,"faqs":141,"seo_title":142,"seo_description":12,"update_tm":143,"read_time":144,"preview_page_count":4},1649267921044,"https://us-avatar.wpscdn.com/avatar/1800007509477c92dfb?_k=1786009248482753345","Neoplasia 51 (2024) 100984  \nContents lists available at ScienceDirect  \nNeoplasia  \njournal [homepage:](homepage: www.elsevier.com/locate/neo)[ www.elsevier.com/locate/neo](homepage: www.elsevier.com/locate/neo)  \n| Original Research\u003Cbr>ST6GAL1 is associated with poor response to chemoradiation in rectal cancer |  |  | |\n| --- | --- | --- | --- |\n| Mary Smithson a, 1, Sameer Al Diffalhab, 1, Regina K. Irwin a, Gregory Williams a,\u003Cbr>M. Chandler McLeod a, Vivek Somasundarama, Susan L. Bellisc, Karin M. Hardimana, d, *\u003Cbr>a Department of Surgery, University of Alabama at Birmingham, Birmingham, Al 35294, USA b Department of Pathology, University of Alabama at Birmingham, Birmingham, Al 35294, USA\u003Cbr>c Department of Cell, Developmental, and Integrative Biology, University of Alabama at Birmingham, Birmingham, Al 35294, USA d Department of Surgery, Birmingham Veterans Affairs Medical Center, Birmingham, Al 35294, USA |  |  |  |\n| A R T I C L E I N F O |  | A B S T R A C T |  |\n| Keywords:\u003Cbr>ST6GAL1 Radiation resistance Sialylation\u003Cbr>Rectal cancer |  | Introduction: Colorectal cancer is the third most common cause of cancer death. Rectal cancer makes up a third of all colorectal cases. Treatment for locally advanced rectal cancer includes chemoradiation followed by surgery. We have previously identified ST6GAL1 as a cause of resistance to chemoradiation in vitro and hypothesized that it would be correlated with poor response in human derived models and human tissues.\u003Cbr>Methods: Five organoid models were created from primary human rectal cancers and ST6GAL1 was knocked down via lentivirus transduction in one model. ST6GAL1 and Cleaved Caspase-3 (CC3) were assessed after chemoradiation via immunostaining. A tissue microarray (TMA) was created from twenty-six patients who underwent chemoradiation and had pre- and post-treatment specimens of rectal adenocarcinoma available at our institution. Immunohistochemistry was performed for ST6GAL1 and percent positive cancer cell staining was assessed and correlation with pathological grade of response was measured.\u003Cbr>Results: Organoid models were treated with chemoradiation and both ST6GAL1 mRNA and protein significantly increased after treatment. The organoid model targeted with ST6GAL1 knockdown was found to have increased CC3 after treatment. In the tissue microarray, 42 percent of patient samples had an increase in percent tumor cell staining for ST6GAL1 after treatment. Post-treatment percent staining was associated with a worse grade of treatment response (p = 0.01) and increased staining post-treatment compared to pre-treatment was also associated with a worse response (p = 0.01).\u003Cbr>Conclusion: ST6GAL1 is associated with resistance to treatment in human rectal cancer and knockdown in an organoid model abrogated resistance to apoptosis caused by chemoradiation. |  |\n\nIntroduction  \nColorectal cancer is the third most common cause of cancer death in both men and women. Rectal cancer makes up a third of all colorectal cases and is rising [1]. Treatment for locally advanced rectal cancer includes chemoradiation followed by surgery but response to treatment is variable. About 20 percent of patients have a complete response to chemoradiation, likely do not need surgery, and have been found to exhibit higher 5-year disease-free survival rates [2,3]. While this is promising, we have little understanding of predictors of response.  \nAltered glycosylation, including hypersialylation, has been identified  \nas one of the hallmarks of cancer [4,5]. ST6GAL1 is the primary enzyme responsible for α2-6 sialylation of N-glycans on select glycoproteins and is increased relative to normal tissues in multiple types of cancer including gastric, pancreatic and colon cancers [6,7]. ST6GAL1 has been associated with tumor progression and therapeutic resistance in pancreatic cancer models [8]. We recently showed that knockdown (KD) of ST6GAL1 decreases resistance to chemoradiation in vitro in colorectal ade","cbCaiiR29QIPFxex","https://ap.wps.com/l/cbCaiiR29QIPFxex","pdf",8604924,"English","# Introduction\n## Treatment variability and predictors\n## ST6GAL1, sialylation, and therapeutic resistance\n# Methods\n## Organoid model generation and knockdown\n## Immunostaining and tissue microarray analysis\n# Results\n## ST6GAL1 induction after chemoradiation\n## Cleaved Caspase-3 changes with ST6GAL1 knockdown\n## Correlation between ST6GAL1 staining and response grade\n# Conclusion","[{\"question\":\"What role does ST6GAL1 have in rectal cancer response to chemoradiation?\",\"answer\":\"ST6GAL1 is associated with resistance to chemoradiation. Higher ST6GAL1 levels after treatment correlate with a worse pathological grade of response in patient samples.\"},{\"question\":\"How were organoid models used to test ST6GAL1 during chemoradiation?\",\"answer\":\"Five organoid models derived from primary rectal cancers were treated with chemoradiation, and ST6GAL1 and Cleaved Caspase-3 were assessed after treatment. One model included ST6GAL1 knockdown via lentiviral transduction to evaluate changes in apoptosis.\"},{\"question\":\"What did the tissue microarray show about ST6GAL1 staining and outcomes?\",\"answer\":\"In the tissue microarray, 42% of samples showed increased ST6GAL1-positive tumor cell staining after chemoradiation. Post-treatment increased staining and worse response grades were significantly correlated.\"}]","ST6GAL1 is associated with poor response to chemoradiation in rectal cancer - Original Research - Abstract | PDF",1790008014,18]